Polyrizon (PLRZ) Current Assets (2023 - 2025)
Polyrizon's (PLRZ) quarterly Current Assets came in at $12.9 million in Q4 2025, up 384.73% YoY from $2.7 million in Q4 2024, and down 19.79% on a QoQ basis from $16.0 million in Q2 2025.
Polyrizon (PLRZ) Current Assets (2023 - 2025) Analysis & Trends
Polyrizon (PLRZ) has 3 years of Current Assets data on file, last reported at $12.9 million in Q4 2025.
- Quarterly Current Assets rose 384.73% year-over-year to $12.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.9 million (up 384.73% YoY) and the FY2025 annual result came in at $12.9 million, up 384.73% from the prior year.
- Current Assets declined to $12.9 million in Q4 2025, from $16.0 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $16.0 million in Q2 2025 to a low of $54000.0 in Q4 2023.
- A 3-year average of $7.9 million and a median of $7.8 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets surged 4812.96% — and 2025, when it surged 384.73%.
- Tracing PLRZ's Current Assets over 3 years: stood at $54000.0 in 2023, then surged by 4812.96% to $2.7 million in 2024, then surged by 384.73% to $12.9 million in 2025.
- The last three Current Assets figures came in at $12.9 million (Q4 2025), $16.0 million (Q2 2025), and $2.7 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Polyrizon | 7.27 Mn | -4.22 Mn | - | 12.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.86 Mn |
| Jun 30, 2025 | 16.03 Mn |
| Dec 31, 2024 | 2.65 Mn |
| Dec 31, 2023 | 54,000.00 |